264 related articles for article (PubMed ID: 21599570)
1. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
2. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
3. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
[TBL] [Abstract][Full Text] [Related]
4. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
[TBL] [Abstract][Full Text] [Related]
5. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension.
Zateyshchikov DA; Minushkina LO; Brovkin AN; Savel'eva EG; Zateyshchikova AA; Manchaeva BB; Nikitin AG; Sidorenko BA; Nosikov VV
Fundam Clin Pharmacol; 2007 Aug; 21(4):437-43. PubMed ID: 17635183
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats.
Bertera F; Di Verniero CA; Mayer MA; Chiappetta D; Buontempo F; Polizio AH; Taira CA; Höcht C
Xenobiotica; 2012 Feb; 42(2):206-19. PubMed ID: 21892881
[TBL] [Abstract][Full Text] [Related]
7. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol.
Si D; Wang J; Xu Y; Chen X; Zhang M; Zhou H
J Cardiovasc Pharmacol; 2014 Oct; 64(4):306-9. PubMed ID: 25291495
[TBL] [Abstract][Full Text] [Related]
8. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
9. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo.
Kindermann M; Maack C; Schaller S; Finkler N; Schmidt KI; Läer S; Wuttke H; Schäfers HJ; Böhm M
Circulation; 2004 Jun; 109(25):3182-90. PubMed ID: 15184276
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
[TBL] [Abstract][Full Text] [Related]
12. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension.
Miki S; Masumura H; Kaifu Y; Yuasa S
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982
[TBL] [Abstract][Full Text] [Related]
16. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of carvedilol in older and younger patients.
Morgan T; Anderson A; Cripps J; Adam W
J Hum Hypertens; 1990 Dec; 4(6):709-15. PubMed ID: 2096213
[TBL] [Abstract][Full Text] [Related]
18. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
Chan SW; Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):767-90. PubMed ID: 22621216
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
20. Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
Rau T; Düngen HD; Edelmann F; Waagstein F; Lainščak M; Dimković S; Apostolović S; Nešković AN; Haverkamp W; Gelbrich G; Eschenhagen T
Clin Pharmacol Ther; 2012 Jul; 92(1):21-8. PubMed ID: 22617224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
